Memphasys Ltd (AU:MEM) has released an update.
Memphasys Ltd announces a strategic three-year equine fertility study to advance the commercialization of its Felix™ device, targeting the artificial insemination market projected to grow robustly through 2032. Collaborating with the University of Newcastle and EquiBreedUK Ltd, the study aims to establish Felix™ as a premier technology for equine sperm selection, with expecting commercial outcomes within a year. The study’s success could enable rapid market penetration, leveraging Memphasys’s entry into wider animal fertility markets without the need for significant device modifications.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
